secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adverum Biotechnologies, Inc. (—)
CIK:        0001501756
Form:       8-K
Filed at:   2025-11-21T23:59:59+00:00
Accession:  0001193125-25-291327
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.02, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adverum terminates Durham lease, issues $7.4M note; Phase 3 ARTEMIS fully enrolled (284 patients)
--------------------------------------------------------------------------------

- Terminated lease at 14 TW Alexander Drive, Durham, NC effective Nov 19, 2025; pays $0.1M cash and releases $7.4M promissory note from escrow.
- Promissory note matures Jan 2031 or earlier if $150M annual revenue/royalties from Ixo-vec; accelerates upon change of control.
- Completed target enrollment of 284 patients in pivotal Phase 3 ARTEMIS trial on Nov 19, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501756/000119312525291327/0001193125-25-291327-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501756/000119312525291327/d88122d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-291327

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer